Hear from Robert Maloney, MD, about what to expect—and what he's excited about—for this year's 2023 Controversies in Modern Eye Care meeting held this April in Los Angeles, California.

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

Flavio Mantelli, MD, PhD, Chief Medical Officer at Dompé, shares about the company's role in nerve growth factor (NGF) applications in ophthalmic disease and other human indications.

Protecting children’s eye health will demand a focus on vision and learning through better nutrition, myopia management, and disease prevention.

These 8 pearls will help improve your patient care, practice management, and more.

Danica Marrelli, OD, FAAO, shares key highlights from her presentation, which she presented during the Glaucoma 360 meeting held this year in San Francisco.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

Kristen Ingenito, MBA, gives key takeaways from her G360 presentation, "A bird’s eye view of innovation."

Shan Lin, MD, gives key takeaways from his G360 presentation, "The latest in IOLs: When and how to use them?"

Robert Stamper, MD, gives key takeaways from his G360 presentation, "Home tonometry: Worth the pressure?"

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

A look back on what's happened in optometry during the week of Jan. 28-Feb. 2.

All new and existing IDOC inventory management accounts will receive an additional annual benefit as part of their initiative to increase optical profitability in independent practices.

Second global virtual event on myopia management scheduled for February 16, 2023.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

Kicking off AMD Awareness Month, give us your thoughts!

As our dependence on technology progresses, we have seen tremendous impact on all aspects of our lives—including our kids’ eyes and vision.

Researchers found that the use of atropine drops after glaucoma surgery may impact vision and prolong rehabilitation time.

A look back on what's happened in optometry during the week of Jan. 21-Jan. 26.